Inpatient | Outpatient | ||||
---|---|---|---|---|---|
Category | Resistance phenotype | n | (%) | n | (%) |
Susceptible to all other agents | - | 418 | (4.1) | 245 | (5.7) |
Single-drug resistant | Eryth | 1409 | (13.7) | 1200 | (27.8) |
Cipro | 232 | (2.2) | 92 | (2.1) | |
Gent | 8 | (0.1) | 3 | (0.1) | |
Clinda | 4 | (0.0)c | 5 | (0.1) | |
Double-drug resistant | Cipro, Eryth | 1854 | (18.0) | 870 | (20.2) |
Eryth, Clinda | 114 | (1.1) | 104 | (2.4) | |
Cipro, Clinda | 62 | (0.6) | 23 | (0.5) | |
Cipro, Gent | 8 | (0.1) | 12 | (0.3) | |
Cipro, SXT | 14 | (0.1) | 2 | (0.0)c | |
Eryth, SXT | 2 | (0.0)c | 1 | (0.0)c | |
Eryth, Gent | 10 | (0.1) | 1 | (0.0)c | |
Gent, SXT | 2 | (0.0)c | 0 | (0.0) | |
Multidrug-resistant | Cipro, Eryth, Clinda | 4915 | (47.6) | 1417 | (32.8) |
Cipro, Eryth, Gent | 30 | (0.3) | 18 | (0.4) | |
Cipro, Eryth, SXT | 23 | (0.2) | 7 | (0.2) | |
Cipro, Gent, SXT | 18 | (0.2) | 10 | (0.2) | |
Eryth, Clinda, Gent | 5 | (0.0) | 5 | (0.1) | |
Cipro, Clinda, Gent | 6 | (0.1) | 3 | (0.1) | |
Eryth, Clinda, SXT | 2 | (0.0)c | 1 | (0.0)c | |
Eryth, Gent, SXT | 0 | (0.0) | 1 | (0.0)c | |
Cipro, Clinda, SXT | 2 | (0.0)c | 0 | (0.0) | |
Cipro, Eryth, Lin | 3 | (0.0)c | 0 | (0.0) | |
Cipro, Eryth, Clinda, Gent | 858 | (8.3) | 214 | (5.0) | |
Cipro, Eryth, Clinda, SXT | 58 | (0.6) | 14 | (0.3) | |
Cipro, Eryth, Gent, SXT | 12 | (0.1) | 4 | (0.1) | |
Eryth, Clinda, Gent, SXT | 2 | (0.0)c | 0 | (0.0) | |
Cipro, Clinda, Gent, SXT | 2 | (0.0)c | 0 | (0.0) | |
Cipro, Eryth, Clinda, Gent, SXT | 247 | (2.4) | 63 | (1.5) | |
Total n | 10,320 | 4,315 |